To provide a comprehensive state-of-the-art review of the emerging role of urine leukotriene E4 (uLTE4) as a biomarker in the diagnosis of chronic rhinosinusitis (CRS), aspirin-exacerbated respiratory disease (AERD), and asthma.
Data Sources
Ovid MEDLINE(R), Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus.
Review Methods
A state-of-the-art review was performed investigating the role of uLTE4 as a diagnostic biomarker, predictor of disease severity, and potential marker of selected therapeutic efficacy.
Conclusions
uLTE4 has been shown to be a reliable and clinically relevant biomarker for CRS, AERD, and asthma. uLTE4 is helpful in ongoing efforts to better endotype patients with CRS and to predict disease severity.
Implications for Practice
Aside from being a diagnostic biomarker, uLTE4 is also able to differentiate aspirin-tolerant patients from patients with AERD and has been associated with objective disease severity in patients with CRS with nasal polyposis. uLTE4 levels have also been shown to predict response to medical therapy, particularly leukotriene-modifying agents.
DeCondeASSolerZM.Chronic rhinosinusitis: epidemiology and burden of disease. Am J Rhinol Allergy. 2016;30(2):134-139.
2.
HalawiAMSmithSSChandraRK.Chronic rhinosinusitis: epidemiology and cost. Allergy Asthma Proc. 2013;34(4):328-334.
3.
FokkensWJLundVJHopkinsC, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(suppl S29):1-464.
4.
OrlandiRRKingdomTTHwangPH, et al. International consensus statement on allergy and rhinology: rhinosinusitis. Int Forum Allergy Rhinol. 2016;6(suppl 1):S22-S209.
5.
LowCMKeoghKASabaES, et al. Chronic rhinosinusitis in eosinophilic granulomatosis with polyangiitis: clinical presentation and antineutrophil cytoplasmic antibodies. Int Forum Allergy Rhinol. 2020;10(2):217-222.
6.
HopkinsC.Chronic rhinosinusitis with nasal polyps. N Engl J Med. 2019;381(1):55-63.
7.
LalDHopkinsCDivekarRD.SNOT-22-based clusters in chronic rhinosinusitis without nasal polyposis exhibit distinct endotypic and prognostic differences. Int Forum Allergy Rhinol. 2018;8(7):797-805.
8.
BachertCHanJKWagenmannM, et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management. J Allergy Clin Immunol. 2021;147(1):29-36.
9.
KlinglerAIStevensWWTanBK, et al. Mechanisms and biomarkers of inflammatory endotypes in chronic rhinosinusitis without nasal polyps. J Allergy Clin Immunol. 2021;147(4):1306-1317.
10.
HanJK.Subclassification of chronic rhinosinusitis. Laryngoscope. 2013;123(suppl 2):S15-S27.
11.
TomassenPVandeplasGVan ZeleT, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137(5):1449-1456.e1444.
12.
LaidlawTM.Clinical updates in aspirin-exacerbated respiratory disease. Allergy Asthma Proc. 2019;40(1):4-6.
13.
JenkinsCCostelloJHodgeL.Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ. 2004;328(7437):434.
14.
RajanJPWineingerNEStevensonDDWhiteAA.Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. J Allergy Clin Immunol. 2015;135(3):676-681.e671.
15.
KuruvillaMEVanijcharoenkarnKLevyJM.The role of mast cells in aspirin-exacerbated respiratory disease (AERD) pathogenesis: implications for future therapeutics. J Asthma Allergy. 2020;13:463-470.
16.
LaidlawTM.Pathogenesis of NSAID-induced reactions in aspirin-exacerbated respiratory disease. World J Otorhinolaryngol Head Neck Surg. 2018;4(3):162-168.
17.
RolandLTWangHMehtaCC, et al. Longitudinal progression of aspirin-exacerbated respiratory disease: analysis of a national insurance claims database. Int Forum Allergy Rhinol. 2019;9(12):1420-1423.
18.
ChobyGO’BrienEKSmithA, et al. Elevated urine leukotriene E4 is associated with worse objective markers in nasal polyposis patients. Laryngoscope. 2021;131(5):961-966.
19.
DivekarRHaganJRankM, et al. Diagnostic utility of urinary LTE4 in asthma, allergic rhinitis, chronic rhinosinusitis, nasal polyps, and aspirin sensitivity. J Allergy Clin Immunol Pract. 2016;4(4):665-670.
20.
RabinovitchN.Urinary leukotriene E4 as a biomarker of exposure, susceptibility and risk in asthma. Immunol Allergy Clin North Am. 2012;32(3):433-445.
21.
HaganJBLaidlawTMDivekarR, et al. Urinary leukotriene E4 to determine aspirin intolerance in asthma: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2017;5(4):990-997.e991.
22.
RabinovitchN.Urinary leukotriene E4. Immunol Allergy Clin North Am. 2007;27(4):651-664.
23.
GyllforsPKumlinMDahlenSEGaberFEhrsPODahlenB.Relation between bronchial responsiveness to inhaled leukotriene D4 and markers of leukotriene biosynthesis. Thorax. 2005;60(11):902-908.
24.
FregoneseLSilvestriMSabatiniFRossiGA.Cysteinyl leukotrienes induce human eosinophil locomotion and adhesion molecule expression via a CysLT1 receptor-mediated mechanism. Clin Exp Allergy. 2002;32(5):745-750.
25.
LeeERobertsonTSmithJKilfeatherS.Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals. Am J Respir Crit Care Med. 2000;161(6):1881-1886.
26.
LaidlawTMLevyJM.NSAID-ERD syndrome: the new hope from prevention, early diagnosis, and new therapeutic targets. Curr Allergy Asthma Rep. 2020;20(4):10.
27.
KumlinMDahlenBBjorckTZetterstromOGranstromEDahlenSE.Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics. Am Rev Respir Dis. 1992;146(1):96-103.
28.
KumlinMStensvadFLarssonLDahlenBDahlenSE.Validation and application of a new simple strategy for measurements of urinary leukotriene E4 in humans. Clin Exp Allergy. 1995;25(5):467-479.
29.
ArmstrongMLiuAHHarbeckRReisdorphRRabinovitchNReisdorphN.Leukotriene-E4 in human urine: comparison of on-line purification and liquid chromatography–tandem mass spectrometry to affinity purification followed by enzyme immunoassay. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877(27):3169-3174.
30.
HoffmanBCRabinovitchN.Urinary leukotriene E4 as a biomarker of exposure, susceptibility, and risk in asthma: an update. Immunol Allergy Clin North Am. 2018;38(4):599-610.
31.
KumlinM.Measurements of leukotrienes in the urine: strategies and applications. Allergy. 1997;52(2):124-135.
32.
LuekeAJMeeusenJWDonatoLJGrayAVButterfieldJHSaengerAK.Analytical and clinical validation of an LC-MS/MS method for urine leukotriene E4: a marker of systemic mastocytosis. Clin Biochem. 2016;49(13-14):979-982.
33.
AsanoKLillyCMO’DonnellWJ, et al. Diurnal variation of urinary leukotriene E4 and histamine excretion rates in normal subjects and patients with mild-to-moderate asthma. J Allergy Clin Immunol. 1995;96(5, pt 1):643-651.
34.
VachierIKumlinMDahlenSEBousquetJGodardPChanezP.High levels of urinary leukotriene E4 excretion in steroid treated patients with severe asthma. Respir Med. 2003;97(11):1225-1229.
35.
BochenekGStachuraTSzafraniecK, et al. Diagnostic accuracy of urinary LTE4 measurement to predict aspirin-exacerbated respiratory disease in patients with asthma. J Allergy Clin Immunol Pract. 2018;6(2):528-535.
36.
RabinovitchNZhangLGelfandEW.Urine leukotriene E4 levels are associated with decreased pulmonary function in children with persistent airway obstruction. J Allergy Clin Immunol. 2006;118(3):635-640.
37.
RabinovitchNStrandMStuhlmanKGelfandEW.Exposure to tobacco smoke increases leukotriene E4-related albuterol usage and response to montelukast. J Allergy Clin Immunol. 2008;121(6):1365-1371.
38.
RabinovitchNSilveiraLGelfandEWStrandM.The response of children with asthma to ambient particulate is modified by tobacco smoke exposure. Am J Respir Crit Care Med. 2011;184(12):1350-1357.
39.
ChobyGWLeeS.Pharmacotherapy for the treatment of asthma: current treatment options and future directions. Int Forum Allergy Rhinol. 2015;5(suppl 1):S35-S40.
40.
KolmertJGomezCBalgomaD, et al. Urinary leukotriene E4 and prostaglandin D2 metabolites increase in adult and childhood severe asthma characterized by type-2 inflammation. Am J Respir Crit Care Med. 2021;203(1):37-53.
41.
ComhairSAABochenekGBaicker-McKeeS, et al. The utility of biomarkers in diagnosis of aspirin exacerbated respiratory disease. Respir Res. 2018;19(1):210.
42.
SmithCMHawksworthRJThienFCChristiePELeeTH.Urinary leukotriene E4 in bronchial asthma. Eur Respir J. 1992;5(6):693-699.
43.
HigashiNTaniguchiMMitaH, et al. Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol. 2004;113(2):277-283.
44.
SanakMKielbasaBBochenekGSzczeklikA.Exhaled eicosanoids following oral aspirin challenge in asthmatic patients. Clin Exp Allergy. 2004;34(12):1899-1904.
45.
ThorwarthRMScottDWLalDMarinoMJ.Machine learning of biomarkers and clinical observation to predict eosinophilic chronic rhinosinusitis: a pilot study. Int Forum Allergy Rhinol. 2021;11(1):8-15.
46.
SantarelliGDLamKKHanJK.Establishing urinary leukotriene E4 as a diagnostic biomarker for chronic rhinosinusitis with comorbid asthma and atopy. Otolaryngol Head Neck Surg. 2019;161(5):764-769.
47.
JerschowEEdinMLChiY, et al. Sinus surgery is associated with a decrease in aspirin-induced reaction severity in patients with aspirin exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2019;7(5):1580-1588.
BartemesKRChobyGO’BrienEKStokkenJKPavelkoKDKitaH. Mass cytometry reveals unique subsets of T cells and lymphoid cells in nasal polyps from patients with chronic rhinosinusitis (CRS) [published online December 28, 2020]. Allergy.
50.
ChatzopoulosKGutierrezCNGarciaJJStokkenJKChobyGO’BrienEK.Sinonasal mucosal vasculature in yellow nail syndrome and chronic rhinosinusitis with or without polyps. Int Forum Allergy Rhinol. 2020;10(1):128-132.
51.
KuruvillaMELeeFELeeGB.Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol. 2019;56(2):219-233.
52.
BachertCDesrosiersMYHellingsPWLaidlawTM.The role of biologics in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2021;100(1):44-47.
53.
WorkmanADKohanskiMACohenNA.Biomarkers in chronic rhinosinusitis with nasal polyps. Immunol Allergy Clin North Am. 2018;38(4):679-692.
54.
Ramirez-JimenezFVazquez-CoronaASanchez-delaVega ReynosoP, et al. Effect of LTRA in L-ASA challenge for aspirin-exacerbated respiratory disease diagnosis. J Allergy Clin Immunol Pract. 2021;9(4):1554-1561.
55.
San NicoloMHabermannNHavelM. AERD associated nasal polyposis: efficacy of postoperative antileukotriene therapy in comparison with aspirin desensitization. a retrospective study. Int Arch Allergy Immunol. 2020;181(10):790-798.
56.
ChauhanBFJeyaramanMMSingh MannA, et al. Addition of anti-leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma. Cochrane Database Syst Rev. 2017;3:CD010347.
57.
WalgamaESHwangPH.Aspirin-exacerbated respiratory disease. Otolaryngol Clin North Am. 2017;50(1):83-94.
DahlenSEMalmstromKNizankowskaE, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(1):9-14.
60.
PyasiKTufvessonEMoitraS.Evaluating the role of leukotriene-modifying drugs in asthma management: are their benefits ‘losing in translation’?Pulm Pharmacol Ther. 2016;41:52-59.
61.
ZeigerRSSzeflerSJPhillipsBR, et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol. 2006;117(1):45-52.
62.
AschenbrennerDS.New boxed warning for Singulair. Am J Nurs. 2020;120(7):27.
63.
LawSWYWongAYSAnandSWongICKChanEW. Neuropsychiatric events associated with leukotriene-modifying agents: a systematic review. Drug Saf. 2018;41(3):253-265.
64.
Sansing-FosterVHaugNMosholderA, et al. Risk of psychiatric adverse events among montelukast users. J Allergy Clin Immunol Pract. 2021;9(1):385-393.e12.
65.
CaiCYangJHuSZhouMGuoW.Relationship between urinary cysteinyl leukotriene E4 levels and clinical response to antileukotriene treatment in patients with asthma. Lung. 2007;185(2):105-112.
66.
SzeflerSJPhillipsBRMartinezFD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol. 2005;115(2):233-242.
67.
SchneiderTRJohnsCBPalumboMLMurphyKCCahillKNLaidlawTM.Dietary fatty acid modification for the treatment of aspirin-exacerbated respiratory disease: a prospective pilot trial. J Allergy Clin Immunol Pract. 2018;6(3):825-831.
68.
MohebatiAMilneGLZhouXK, et al. Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers. Cancer Prev Res (Phila). 2013;6(7):646-655.
69.
LeighRVethanayagamDYoshidaM, et al. Effects of montelukast and budesonide on airway responses and airway inflammation in asthma. Am J Respir Crit Care Med. 2002;166(9):1212-1217.
